Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Letter

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2403-

  Dumont, Amaury G ^a   Reynoso, David G ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; IMATINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REACTIVATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IC 50; IN VITRO STUDY; LETTER; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; TREATMENT DURATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; MICE; MUTATION; PROPYLENE GLYCOLS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-KIT; SPHINGOSINE;

EID: 79952749744     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3383     Document Type: Letter

References (5)

1. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010;70:5438-47.
2. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
3. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
4. Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, et al. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol 2009;36:302-11.
5. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, et al. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol 2010;5:93-104.